Traders Buy Large Volume of DexCom Call Options (NASDAQ:DXCM)

DexCom, Inc. (NASDAQ:DXCM) was the target of some unusual options trading on Thursday. Investors bought 10,495 call options on the stock. This is an increase of approximately 87% compared to the average volume of 5,616 call options.

Insider Activity at DexCom

In other DexCom news, COO Jacob Steven Leach sold 14,639 shares of the stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $134.41, for a total transaction of $1,967,627.99. Following the completion of the transaction, the chief operating officer now directly owns 273,913 shares in the company, valued at $36,816,646.33. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, CFO Jereme M. Sylvain sold 3,363 shares of the business’s stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $116.73, for a total value of $392,562.99. Following the transaction, the chief financial officer now directly owns 71,142 shares of the company’s stock, valued at approximately $8,304,405.66. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Jacob Steven Leach sold 14,639 shares of the stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $134.41, for a total value of $1,967,627.99. Following the sale, the chief operating officer now owns 273,913 shares in the company, valued at $36,816,646.33. The disclosure for this sale can be found here. Insiders have sold a total of 189,375 shares of company stock valued at $25,530,859 in the last 90 days. 0.41% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On DexCom

Institutional investors and hedge funds have recently modified their holdings of the business. Stableford Capital II LLC boosted its holdings in shares of DexCom by 2.1% in the fourth quarter. Stableford Capital II LLC now owns 4,367 shares of the medical device company’s stock valued at $563,000 after buying an additional 88 shares during the period. D Orazio & Associates Inc. lifted its position in DexCom by 0.8% in the 4th quarter. D Orazio & Associates Inc. now owns 12,366 shares of the medical device company’s stock valued at $1,534,000 after acquiring an additional 93 shares in the last quarter. Gulf International Bank UK Ltd boosted its stake in DexCom by 0.3% in the 1st quarter. Gulf International Bank UK Ltd now owns 32,075 shares of the medical device company’s stock worth $4,448,000 after purchasing an additional 93 shares during the period. EverSource Wealth Advisors LLC increased its holdings in DexCom by 10.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the medical device company’s stock worth $133,000 after purchasing an additional 98 shares in the last quarter. Finally, Harbor Investment Advisory LLC increased its holdings in DexCom by 13.1% during the 1st quarter. Harbor Investment Advisory LLC now owns 864 shares of the medical device company’s stock worth $120,000 after purchasing an additional 100 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

DXCM has been the topic of several research analyst reports. StockNews.com cut DexCom from a “buy” rating to a “hold” rating in a report on Tuesday. Citigroup increased their price objective on shares of DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a report on Wednesday, April 3rd. Royal Bank of Canada assumed coverage on shares of DexCom in a research note on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 target price for the company. Raymond James upped their target price on shares of DexCom from $147.00 to $151.00 and gave the stock a “strong-buy” rating in a research report on Tuesday, January 23rd. Finally, UBS Group raised their price target on shares of DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a report on Wednesday, April 10th. Three analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, DexCom currently has a consensus rating of “Moderate Buy” and a consensus target price of $141.40.

DexCom Trading Up 0.1 %

Shares of NASDAQ DXCM opened at $138.01 on Friday. The company has a quick ratio of 2.48, a current ratio of 2.84 and a debt-to-equity ratio of 1.18. DexCom has a twelve month low of $74.75 and a twelve month high of $142.00. The company’s fifty day moving average is $130.98 and its 200-day moving average is $118.02. The stock has a market cap of $54.66 billion, a price-to-earnings ratio of 105.35, a P/E/G ratio of 2.37 and a beta of 1.20.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, February 8th. The medical device company reported $0.50 earnings per share for the quarter, topping the consensus estimate of $0.43 by $0.07. DexCom had a return on equity of 28.31% and a net margin of 14.95%. The firm had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.02 billion. During the same period in the previous year, the company posted $0.34 earnings per share. The company’s revenue for the quarter was up 26.9% on a year-over-year basis. Equities research analysts predict that DexCom will post 1.76 EPS for the current year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.